Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Capecitabine (Xeloda) in Frail Patients With Untreated Metastatic Colorectal Cancer

NCT00203411 is registered in ClinicalTrials.gov with Translational Oncology Research International as lead sponsor.

NCT NCT00203411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00203411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Capecitabine (Xeloda) in Frail Patients With Untreated Metastatic Colorectal Cancer
Lead sponsor
Translational Oncology Research International
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
March 31, 2011
Enrollment
45 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer